Patient Care
    Liu Zhuo-Wei
    Title Vice-President and Professor
    Profile

    As an oncological urologist, Dr. Liu specializes in the surgical treatment of urinary tumors, especially in robotic and minimally invasive laparoscopic surgeries, as well as the comprehensive treatment of bladder cancer and testicular cancer, and the surgical treatment of children's tumors. He is one of the first surgeons in China to carry out robot-assisted/laparoscopic retroperitoneal lymph node dissection for testicular cancer and ultra-expanded lymph node dissection for bladder cancer. He has been awarded the Outstanding Contribution Award for the Highest Volume of 3-4 level difficulty Surgeries as the chief professor of Sun Yat-sen University Cancer Center. He has undertaken more than 10 research projects with funding from the National Natural Science Foundation of China and the Guangdong Natural Science Foundation, and published more than 40 articles as the first author (corresponding author), participated in editing six academic works, and served as the deputy chief editor of Bladder Cancer.

    Schedule Thursday morning and afternoon
    Zhou Fangjian
    Title Professor, Director of the Department of Urology
    Profile

    Modified radical cystectomy
    Our group has made several modifications to the traditional radical cystectomy. The first is a modified technique to prevent complications related to stoma and ileoureteral anastomosis in patients undergoing ileal conduit diversion. The second is a modified technique for neourethral anastomosis in orthotopic neobladder reconstruction. Both of the two modifications have been widely accepted by peers.

    Nephron sparing operation
    Our group pays a lot of attention to nephron sparing operation. As more and more small renal mass being detected accidentally by body exam, and the prolonged  life span, preserving the kidney is more and more important. Our group made some modification to the traditional nephron sparing operation, which significantly reduced the postoperative complication.

    The mechanisms of Bladder cancer metastasis
    Metastasis is the main reason of failure in cancer treatment. Bladder cancer with metastasis is incurable. Hence exploring the mechanisms of Bladder cancer metastasis can provide new idea in the treatment of bladder cancer. Our group demonstrated that up-regulation of Nkx2.8 inhibited epithelial-mesenchymal transition (EMT), an early key event in cancer metastasis, in bladder cancer cells. The research is supported by the grants from the Natural Science Foundation of China (No. 81272810) and the Natural Science Foundation of Guangdong Province, China(No. S2012010009466).

    1995, The first award for“The series studies of renal stone and renal function” Hunan Province Science and Technology Association

    Schedule Monday morning
    Han Hui
    Title Professor and Deputy Director
    Profile

    Prof. Han is specialized in treating patients with genitourinary system cancers, including bladder, kidney, prostate,adrenal gland, ureter, urethra, testis, epididymis, spermatic cord, and penis and so on. He is good at various kinds of urological operations, especially retroperitoneal lymph node dissection and inguinal lymphadenectomy.

    Prof. Han perform laparscopic and open procedures to treat these cancers, often in a multi-disciplinary team approach with the integration of expertise by medical oncology and/or radiation oncology. He also pursued technical innovations which have transformed the management of these cancers including open inguinal lymphadenectomy, laparoscopic retroperitoneal lymph node dissection, open/ laparoscopic radical nephrectomy and laparoscopic radical prostatectomy.

    Annually, Prof. Han perform approximately 100 partial/radical nephrectomy procedures for kidney cancer, 20 prostatectomy procedures for prostate cancer, 20 cystectomy procedures for bladder cancer, 20 lymph node dissections for penile cancer, and 15 retroperitoneal lymph node dissections for testis cancer. He also has unique expertise in managing rare urologic cancers and salvage procedures for recurrent cancers of the bladder and prostate that have failed initial therapy with surgery or other treatments.

    Schedule
    Li Yonghong
    Title Associate Professor and Deputy Director
    Profile

    Dr. Li specializes in diagnosis and treatment of genitourinary cancers. He focus on prostate cancer, including early diagnosis of prostate cancer with elevated PSA, open or robotic-assisted radical prostatectomy, prostate cryoablation, and comprehensive treatment of prostate cancer. He is a recognized expert in prostate cryoablation.

     
    Last Updated on: February 2016
    Schedule Monday afternoon, Friday afternoon
    Yao Kai
    Title Associate Professor and Deputy Director
    Profile

    Doctor Yao is specialized in treating patients with genitourinary system cancers, including bladder, kidney, prostate, adrenal gland, ureter, urethra, testis, epididymis, spermatic cord, and penis and so on. He is good at various kinds of urological operations, especially radical inguinal lymphadenectomy. Doctor Yao perform laparscopic and open procedures to treat these cancers, often in a multi-disciplinary team approach with the integration of expertise by medical oncology and/or radiation oncology. He also pursued technical innovations which have transformed the management of these cancers including open inguinal lymphadenectomy, laparoscopic retroperitoneal lymph node dissection, open/ laparoscopic radical nephrectomy and laparoscopic radical prostatectomy. He also has unique expertise in managing rare urologic cancers and salvage procedures for recurrent cancers of the penis and kidney that have failed initial therapy with surgery or other treatments.

    Schedule Tuesday Afternoon
    Qin Zike
    Title Professor, Chief Physician
    Profile Bladder cancer, kidney cancer, prostate cancer, testicular cancer, and other comprehensive treatment.
    Schedule Wednesday morning
    Dong Pei
    Title Attending doctor
    Profile
    Surgical treatment of urologic oncology  and anti-prostate cancer drug research. The mechanism of prostate cancer progression. In recent years, we investigated Prohibitin plays an important role in the progression of castration-resistant prostate cancer (CRPC) through regulating SREBP and E2F signal pathways.We are now studying  the role of prohibitin regulate intratumoral androgen synthesis leading to CRPC progression. The target of this study is to discover the mechanism of Prohibitin promoted progression of CRPC and provide new target for CRPC therapy.
    Schedule Friday morning and afternoon
    Wu Zhiming
    Title Attending physician
    Profile

    Dr. Wu is a urologic surgeon whose practice focuses on the comprehensive care of people with genitourinary malignancies, with an emphasis on testis, prostate, kidney, bladder cancer. As part of a multidisciplinary team of surgeons, radiation oncologists, pathologists, and medical oncologists, he strive to provide the optimal care for each patient’s unique situation. In addition to standard-of-care options, he participate in clinical trials and studies aimed at improving patients’ outcomes following multidisciplinary treatment for prostate cancer, kidney cancer and testis cancer.

    Schedule
    Zhang Zhiling
    Title Associate Professor
    Profile

    I graduated at Guangzhou Medical University as a  MD in 2006. During 2006-2012, I finished my post graduated training in Sun Yat-Sen University  Cancer Center. After that I was trained as a research fellow in one of the most famous kidney cancer center- The Cleveland Clinic. From then on I work as a full-time faculty in Sun Yat-Sen University  Cancer Center as a urologist. I am skilled in treating urological cancer, especially renal cancer, bladder cancer and prostate cancer with both minimally invasive surgery and open surgery.

    Schedule

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.